Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

News

Article

July 29, 2024

Myeloma-Related Questions to Ask After Diagnosis

Author(s):

Brielle Benyon

Fact checked by:

Ashley Chan

From finding reputable info to asking, “Do I really need all these drugs?” experts weighed in on important questions to ask after a myeloma diagnosis.

Image of a person pointing their finger at an array of question marks.

We spoke with three myeloma experts about myeloma-related questions patients should ask their doctors after a diagnosis.

The treatment landscape for multiple myeloma is changing drastically, with more treatments and drug combinations than ever before.

Like any cancer diagnosis, learning that you have myeloma could be overwhelming. So, we asked hematology experts what patients should ask their clinical care team soon after receiving their diagnosis. Here is what they had to say.

READ MORE: Questions Patients Should Ask After a Cancer Diagnosis

Find Reputable Sources for Myeloma Information

“‘Where can I learn more or whom can I learn more from?’ … Patients are treated with myeloma for years and because ... there is a disconnect between how [researchers] have written the trials and the standard treatments and how we actually [use] them, it is tremendously important for patients to feel like they can advocate for the plan that makes the most sense for them.

“So practically, in terms of what I would say to ask your oncologist is, ‘What websites do you trust? What patient support groups can I join?’ I think patient support groups for my patients have been tremendously important because they learn from each other. And they come to me and they're like, ‘Oh, what do you think about stopping my dexamethasone or lowering this medication or that?’ Just because the toxicities of myeloma treatment build up over time, and we are really focused on keeping people in remission and so we have an inherent bias as oncologists to overtreat our patients.”

— Dr. Rahul Banerjee, assistant professor in the clinical research division of Fred Hutchinson Cancer Center

Understand Disease Treatments, Statistics

“I would say for a medical oncologist like myself who sees patients with recurrent disease who have difficulties in getting to a cure, I think the most important question that a patient could ask is, ‘How much should I put faith in the statistics and the numbers that the physicians are giving me in terms of predicting my outcome?’ Because I think the more we treat patients, the more patients surprise themselves — and surprise us many times — where they actually beat the expectations. Currently, in the immunotherapy era, I think many patients do beat the expectations. And I'm not saying this just for patients who will beat expectations, but also for patients who do not meet the expectations. And so, how much of these numbers are really relevant in actually predicting the outcome of a single particular patient? I think it is something that is very contentious. I don't know if we can maybe do studies around that area. But I think this is a little bit of a fallacy when you sit in front of a patient and give numbers. Those numbers really may not apply to that patient.”

— Dr. Nabil Saba, professor in the department of hematology and medical oncology, Emory University

“It really depends on what stage of your treatment you're in. There's so much range in terms of the amount of information one individual wants versus another. But I think always asking, ‘What are my options?’ is beneficial. Understanding the breadth of your options, not just what is recommended so that you're getting what they recommend but understanding the alternatives.

“Myeloma is a bit of a chess match. So you have your move now, but you always have to be planning as a physician, what the move is beyond that, and after that, so I think as a patient, understanding what this current move is, which your other options for that move are and what is ahead of that it's just important, especially in a field that's rapidly changing in the way that myeloma has over the past decade.”

— Dr. Elizabeth O’Donnell, director of Early Detection and Prevention at Dana-Farber Cancer Institute and assistant professor of Medicine at Harvard Medical School

"[Patients should ask], ‘Do I really need all these medications?’ For some people, the answer is ‘Yes, absolutely.’ I [say] ‘Look, you have high-risk cytogenetics. I need to keep you on these medications. I'm very concerned otherwise if we don't.’

“As an example, technically the standard for [Revlimid (lenalidomide)] for myeloma is to keep people on treatment forever, [but] in real life, more studies are emerging around MRD-guided discontinuation. But honestly, some people just hate [Revlimid], they're having side effects from it. They're having financial toxicity from it, etc. And I think asking the doctor, ‘Do I need this drug? Can I switch to something different? Can I stop?’ are all really useful questions.

“As oncologists, we don't hear about the side effects they're having, we don't hear about the financial toxicity. We are notoriously poor at asking our patients, "How are you financially doing with this diagnosis?"

— Dr. Rahul Banerjee

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
Image of doctor with grey hair.
Dr. Mikhael in an interview with CURE
Dr. Ajai Chari in an in interview with CURE
An image of Dr. Patel in an interview with CURE discussing healthy lifestyles in myeloma
Dr. Munshi in an interview with CURE
Dr. Dikran Kazandjian during an interview with CURE
Related Content
Advertisement
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
July 2nd 2025

FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma

Spencer Feldman
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of ronald.
June 25th 2025

Traveling with Multiple Myeloma: A Journey of Adaptation and Hope

Ronald Chin
I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened doors to adventure and connection.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Ronald Chin received a diagnosis of multiple myeloma in January 2017 and has been in remission since October 2023. Catch up on all of Ronald's blogs here!
June 5th 2025

Being in the Present Moment With Multiple Myeloma

Ronald Chin
I reflect on finding peace, purpose and presence after my diagnosis through a creative writing exercise rooted in mindfulness and metaphor.
Grace Allison, B.S.N., RN, OCN, RN-BC, and Erin Mensching, RN-B.S.N., OCN
May 18th 2025

Providing Care and Listening With Compassion During Cancer

Grace Allison, B.S.N., RN, OCN, RN-BC
Related Content
Advertisement
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
July 2nd 2025

FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma

Spencer Feldman
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of ronald.
June 25th 2025

Traveling with Multiple Myeloma: A Journey of Adaptation and Hope

Ronald Chin
I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened doors to adventure and connection.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Ronald Chin received a diagnosis of multiple myeloma in January 2017 and has been in remission since October 2023. Catch up on all of Ronald's blogs here!
June 5th 2025

Being in the Present Moment With Multiple Myeloma

Ronald Chin
I reflect on finding peace, purpose and presence after my diagnosis through a creative writing exercise rooted in mindfulness and metaphor.
Grace Allison, B.S.N., RN, OCN, RN-BC, and Erin Mensching, RN-B.S.N., OCN
May 18th 2025

Providing Care and Listening With Compassion During Cancer

Grace Allison, B.S.N., RN, OCN, RN-BC
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.